Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Interim Results

27 Sep 2006 07:00

Omega Diagnostics Group PLC27 September 2006 Omega Diagnostics Group PLC 26-Sep-2006 Omega Diagnostics Group PLC (formerly Quintessentially English PLC) (the "Company") Interim Results The Company announces its interim results for the six month period to 30th June2006. These interim results do not include any results for Omega DiagnosticsLimited ("Omega"), the acquisition of which was announced on 24th August 2006and unanimously approved by shareholders at the EGM on 18th September 2006. Since the Company's Admission to AIM in March 2004 it has continued to evaluatea number of potential acquisitions and this has resulted in the purchase ofOmega. During the six months ended 30th June 2006, there was a turnover in respect ofthe Company (excluding Omega) of Β£Nil, and a loss after tax of Β£73,218, the bulkof which related to abort fees incurred on prospective acquisitions paid toadvisers undertaking due diligence. No Company directors received anyremuneration during the period and no dividend is recommended. The future Omega manufactures and distributes test kits for tropical and other diseases ona global basis, selling product through a strong distribution network in over100 countries and which it has been involved in for the past 19 years. Omega hasidentified a number of prospective and related acquisitions and intends to growin this way. Michael Gurner will be staying on as a non-executive director and Robert Coe andGraham Ashley have resigned following the EGM. David Evans has become Chairmanand Andrew Shepherd and Kieron Harbinson have joined the Board as ChiefExecutive and Finance Director respectively. For further information: Omega Diagnostics Group PLCMr Michael Gurner, 07768 231 731 Profit and Loss AccountFor the period 01/01/06 to 30/06/06 Note Period Ended 30/06 Period Ended 30/06 /2006 (unaudited) /2005 (unaudited) Β£ Β£ Turnover - -Administrative expenses (75,850) (60,633)Operating Loss (75,850) (60,633)Interest Receivable 2,674 4,382Interest Payable (42) (32)Loss on ordinary activities before taxation 1 (73,218) (56,283)Taxation - -Loss on ordinary activities after taxation (73,218) (56,283)Basic and diluted earnings per Ordinary share (pence) (0.66) (0.50)Dividends per share (pence) 0 0 Balance SheetAs at 30/06/06 Note 30/06/2006 30/06/2005 (unaudited) (unaudited) Β£ Β£ Β£ Β£ Fixed AssetsInvestments 2 2Current AssetsPrepayments 3,825 0Cash at bank in hand 124,820 198,277Current LiabilitiesCreditors: Amounts falling (80,122) (48,120)due within one yearNet current assets 48,523 150,157Total assets less current 48,525 150,159liabilitiesCalled up share capital 2 111,769 111,769Share premium 3 167,867 167,867Profit and loss account (231,111) (129,477)Equity shareholders funds 48,525 150,159Net assets per share (pence) 4 0.43p 1.34p Cash Flow Statement For the period from 01/01/06 to 30/06/06 Note Period Ended 30/06 Period Ended 30/06 /2006 (unaudited) /2005 (unaudited) Β£ Β£ Net cash inflow from operating activities (29,938) (28,677)Returns on investment and servicing of finance:Interest received 2,674 4,382Interest payable (42) (32)Decrease in cash (27,306) (24,327) Notes to the Interim Report 1. Loss on ordinary activities before taxation The loss for the period is representative of operational overheads incurred inthe period. 2. Called up share Capital The issued share capital compromises 11,176,865 ordinary shares of 1p each,consisting of 200 shares of 1p each issued as two Β£1 subscriber shares onincorporation and converted into 1p shares on 23rd February 2004, 6,666,665ordinary shares of 1p each issued on 24th February 2004 and 4,510,000 ordinaryshares of 1p each issued on 18th March 2004. 3. Share premium The share premium represents: Β£ Premium arising on issues of ordinary shares in the period ended 31/12/2004 213,731Expenses of shares issues in the period ending 31/12/2004 (45,864) At 30th June 2006 167,867 4. Net assets per share The calculation of net assets per share is based on the net assets at the end ofthe period of Β£48,525 and on the number of ordinary shares in issue (11,176,865)at 30th June 2006. 5. Preparation of Interim Report The interim financial information for the period from 1 January 2006 to 30thJune 2006 was approved by the directors on 26 September 2006. 6. Financial information The financial information in this statement does not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Mar 20217:00 amRNSContract with Screen4
24th Feb 20217:00 amRNSUK-RTC statement on AbC-19TM rapid antibody test
19th Feb 20211:45 pmRNSDirector/PDMR Shareholding
18th Feb 202110:00 amRNSDirector/PDMR Shareholding
16th Feb 20217:00 amRNSAbC-19TM rapid antibody test performance data
15th Feb 20217:00 amRNSDirector/PDMR Shareholding
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:01 amRNSUK Government contract and trading update
11th Feb 20217:00 amRNSDirectorate Change
8th Feb 20219:05 amRNSSecond Price Monitoring Extn
8th Feb 20219:00 amRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSStatement re Media Comment
2nd Feb 20218:45 amRNSExercise of Options and Total Voting Rights
28th Jan 20211:15 pmRNSExercise of Options and Total Voting Rights
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:35 pmRNSPrice Monitoring Extension
26th Jan 20217:02 amRNSLab-based COVID-19 antibody test service launch
26th Jan 20217:01 amRNSUpdate re AbC-19 Rapid Test
25th Jan 202111:06 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
22nd Jan 202110:15 amRNSExercise of Options and Total Voting Rights
22nd Jan 20219:05 amRNSSecond Price Monitoring Extn
22nd Jan 20219:00 amRNSPrice Monitoring Extension
11th Jan 202111:00 amRNSExercise of Options and Total Voting Rights
29th Dec 20207:01 amRNSUpdate re AbC-19 Rapid Test
29th Dec 20207:00 amRNSAbC-19TM Rapid Test Update
24th Dec 202012:41 pmRNSSecond Price Monitoring Extn
24th Dec 202012:35 pmRNSPrice Monitoring Extension
24th Dec 202012:00 pmRNSMologic CE Mark Rapid Antigen Test
24th Dec 202011:05 amRNSSecond Price Monitoring Extn
24th Dec 202011:00 amRNSPrice Monitoring Extension
11th Dec 20202:05 pmRNSSecond Price Monitoring Extn
11th Dec 20202:00 pmRNSPrice Monitoring Extension
11th Dec 20209:45 amRNSExercise of Options and Total Voting Rights
7th Dec 20208:00 amRNSExercise of Options and Total Voting Rights
2nd Dec 20209:00 amRNSDirector/PDMR Shareholding
30th Nov 20202:30 pmRNSExercise of Options and Total Voting Rights
30th Nov 20207:00 amRNSInterim Results
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:01 pmRNSPrice Monitoring Extension
23rd Nov 20209:45 amRNSExercise of Options and Total Voting Rights
17th Nov 20207:45 amRNSUK-RTC Update
16th Nov 20207:16 amRNSHolding(s) in Company
16th Nov 20207:15 amRNSHolding(s) in Company
13th Nov 20202:05 pmRNSSecond Price Monitoring Extn
13th Nov 20202:00 pmRNSPrice Monitoring Extension
13th Nov 20209:30 amRNSExercise of Options and Total Voting Rights
12th Nov 20203:42 pmRNSUK-RTC Statement
12th Nov 202011:05 amRNSSecond Price Monitoring Extn
12th Nov 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.